Identification of potential synthetic lethal genes to p53 using a computational biology approach

BMC Medical Genomics

Table 6 Comparison of drug sensitivity between two groups of cell lines

Compound	Mean of drug		p-value ⁿ	Targets
	sensitivity ^k
	c1 ^l	c2 ^m
paclitaxel	0.1366	-0.2790	0.0323	PLK1, AURKA, BUB1
hymenialdisine	0.0590	-0.1359	0.2529	CDK1
olomoucine	0.0665	-0.1405	0.2311	CDK1
mercaptopurine	0.1012	-0.2037	0.1134	STK38
tamoxifen citrate	0.1003	-0.2121	0.0976	PRKCH, PRKCI, PRKCZ
imatinib	0.0425	-0.0358	0.3791	PDGFRA
sunitinib	0.0243	-0.0132	0.4384	PDGFRA
sorafenib	0.0801	-0.1779	0.184	PDGFRA, RAF1
DDUG	0.0860	-0.1811	0.1218	CHEK2
choline	0.0390	-0.2779	0.1188	CHKA
rapamycin	-0.1044	0.1784	0.8866	MTOR
everolimus	0.0095	0.1526	0.7188	MTOR
nocodazole	-0.0636	0.0026	0.5937	PLK1, BUB1
cisplatin	-0.1546	0.1984	0.9376	SRPK1
bryostatin	-0.0218	0.0958	0.6602	PKC family
axitinib	-0.0278	0.0589	0.6235	PDGFRA

^k mean of standardized negative log(GI50) values (higher means indicate higher sensitivity).
^l c1: The NCI60 cell lines with functional p53 mutations.
^m c2: The NCI60 cell lines with non-functional p53 mutations or p53 wild-type.
ⁿ The one-sided t-test statistics (hypothesis of higher drug sensitivity in cell lines with functional p53 mutations).

ISSN: 1755-8794